Challenges and progress in developing herpesvirus vaccines (Q40536037)

21 September 2017

1 reference

title

Challenges and progress in developing herpesvirus vaccines (English)

1 reference

21 September 2017

Inglis SC

1 reference

21 September 2017

publication date

1 April 1995

1 reference

21 September 2017

1 reference

inferred from page(s)

published in

Trends in Biotechnology

1 reference

21 September 2017

1 reference

21 September 2017

1 reference

21 September 2017

page(s)

135-142

1 reference

Sequence determination and genetic content of the short unique region in the genome of herpes simplex virus type 1.

21 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

The complete DNA sequence of the long unique region in the genome of herpes simplex virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

DNA sequence and expression of the B95-8 Epstein-Barr virus genome.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

The complete DNA sequence of varicella-zoster virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

The biochemistry and cell biology of antigen processing and presentation

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Investigation of herpes simplex virus type 1 (HSV-1) gene expression and DNA synthesis during the establishment of latent infection by an HSV-1 mutant, in1814, that does not replicate in mouse trigeminal ganglia

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Herpes simplex virus infections during the decade since the licensure of acyclovir

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Immune response of elderly individuals to a live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Primary cytomegalovirus infection in pregnancy. Incidence, transmission to fetus, and clinical outcome

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Genital Herpes in Guinea Pigs: Pathogenesis of the Primary Infection and Description of Recurrent Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Experimental Infection of Guinea Pigs with Varicella-Zoster Virus

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Lymphoma in cotton-top marmosets after inoculation with Epstein-Barr virus: tumor incidence, histologic spectrum antibody responses, demonstration of viral DNA, and characterization of viruses

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Protective effects of Towne cytomegalovirus vaccine against low-passage cytomegalovirus administered as a challenge

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Vaccines for varicella-zoster virus and cytomegalovirus: recent progress

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Varicella-Zoster Virus Transformation of Hamster Embryo Cells

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Transformation of NIH 3T3 cells with cloned fragments of human cytomegalovirus strain AD169

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Bovine herpesvirus-1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Current status and prospects of live varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

In vivo behavior of genetically engineered herpes simplex viruses R7017 and R7020: construction and evaluation in rodents

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Mapping of herpes simplex virus-1 neurovirulence to gamma 134.5, a gene nonessential for growth in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Herpes zoster in an adult recipient of live attenuated varicella vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Vaccine potential of a herpes simplex virus type 1 mutant with an essential glycoprotein deleted

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Replication-defective mutants of herpes simplex virus (HSV) induce cellular immunity and protect against lethal HSV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Protective vaccination against primary and recurrent disease caused by herpes simplex virus (HSV) type 2 using a genetically disabled HSV-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Validation of a first-generation Epstein-Barr virus vaccine preparation suitable for human use.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Novel adjuvant strategies for experimental malaria and AIDS vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Immunity in strain 2 guinea-pigs inoculated with vaccinia virus recombinants expressing varicella-zoster virus glycoproteins I, IV, V or the protein product of the immediate early gene 62

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Biological response of recombinant interleukin-7 on herpes simplex virus infection in guinea-pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

Adjuvant-independent enhanced immune responses to recombinant herpes simplex virus type 1 glycoprotein D by fusion with biologically active interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0167-7799%2800%2988924-6

7 January 2021

10.1016/S0167-7799(00)88924-6

Identifiers

DOI

1 reference

21 September 2017

1 reference